Heart Failure with Preserved Ejection Fraction in Women

Anjan Tibrewala, Clyde W Yancy

Research output: Contribution to journalReview article

Abstract

Heart failure with preserved ejection fraction (HFpEF) is an increasingly prevalent condition, particularly in women. Comorbidities, including older age, obesity, diabetes mellitus, hypertension, and hyperlipidemia, are risk factors and define phenotypic profiles of HFpEF in women. The condition has a relatively high burden of morbidity and mortality, with phenotypic profiles potentially characterizing risk of hospitalization and mortality. Based on limited data, nonpharmacologic and pharmacologic treatments may provide benefit; however, compelling evidence-based, disease-modifying treatments are needed. Many unanswered questions about HFpEF in women warrant further investigation to improve understanding of the disease and provide better patient care.

LanguageEnglish (US)
Pages9-18
Number of pages10
JournalHeart Failure Clinics
Volume15
Issue number1
DOIs
StatePublished - Jan 1 2019

Fingerprint

Diastolic Heart Failure
Sex Characteristics
Heart Failure
Mortality
Hyperlipidemias
Comorbidity
Patient Care
Diabetes Mellitus
Hospitalization
Obesity
Hypertension
Morbidity
Therapeutics

Keywords

  • Diastolic heart failure
  • Heart failure with preserved ejection fraction
  • Sex differences
  • Women

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

@article{0a2eac43c8a645d7a5095552517f3413,
title = "Heart Failure with Preserved Ejection Fraction in Women",
abstract = "Heart failure with preserved ejection fraction (HFpEF) is an increasingly prevalent condition, particularly in women. Comorbidities, including older age, obesity, diabetes mellitus, hypertension, and hyperlipidemia, are risk factors and define phenotypic profiles of HFpEF in women. The condition has a relatively high burden of morbidity and mortality, with phenotypic profiles potentially characterizing risk of hospitalization and mortality. Based on limited data, nonpharmacologic and pharmacologic treatments may provide benefit; however, compelling evidence-based, disease-modifying treatments are needed. Many unanswered questions about HFpEF in women warrant further investigation to improve understanding of the disease and provide better patient care.",
keywords = "Diastolic heart failure, Heart failure with preserved ejection fraction, Sex differences, Women",
author = "Anjan Tibrewala and Yancy, {Clyde W}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.hfc.2018.08.002",
language = "English (US)",
volume = "15",
pages = "9--18",
journal = "Heart Failure Clinics",
issn = "1551-7136",
publisher = "Elsevier Inc.",
number = "1",

}

Heart Failure with Preserved Ejection Fraction in Women. / Tibrewala, Anjan; Yancy, Clyde W.

In: Heart Failure Clinics, Vol. 15, No. 1, 01.01.2019, p. 9-18.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Heart Failure with Preserved Ejection Fraction in Women

AU - Tibrewala, Anjan

AU - Yancy, Clyde W

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Heart failure with preserved ejection fraction (HFpEF) is an increasingly prevalent condition, particularly in women. Comorbidities, including older age, obesity, diabetes mellitus, hypertension, and hyperlipidemia, are risk factors and define phenotypic profiles of HFpEF in women. The condition has a relatively high burden of morbidity and mortality, with phenotypic profiles potentially characterizing risk of hospitalization and mortality. Based on limited data, nonpharmacologic and pharmacologic treatments may provide benefit; however, compelling evidence-based, disease-modifying treatments are needed. Many unanswered questions about HFpEF in women warrant further investigation to improve understanding of the disease and provide better patient care.

AB - Heart failure with preserved ejection fraction (HFpEF) is an increasingly prevalent condition, particularly in women. Comorbidities, including older age, obesity, diabetes mellitus, hypertension, and hyperlipidemia, are risk factors and define phenotypic profiles of HFpEF in women. The condition has a relatively high burden of morbidity and mortality, with phenotypic profiles potentially characterizing risk of hospitalization and mortality. Based on limited data, nonpharmacologic and pharmacologic treatments may provide benefit; however, compelling evidence-based, disease-modifying treatments are needed. Many unanswered questions about HFpEF in women warrant further investigation to improve understanding of the disease and provide better patient care.

KW - Diastolic heart failure

KW - Heart failure with preserved ejection fraction

KW - Sex differences

KW - Women

UR - http://www.scopus.com/inward/record.url?scp=85056585645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056585645&partnerID=8YFLogxK

U2 - 10.1016/j.hfc.2018.08.002

DO - 10.1016/j.hfc.2018.08.002

M3 - Review article

VL - 15

SP - 9

EP - 18

JO - Heart Failure Clinics

T2 - Heart Failure Clinics

JF - Heart Failure Clinics

SN - 1551-7136

IS - 1

ER -